^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19 inhibitor

    Related drugs:
    3d
    Complete remission treated by Bcl-2 inhibitor combined with Blinatumomab as induction treatment for adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation: A multicenter, prospective, randomized controlled, open-label, phase II study (ChiCTR2500111430)
    P2, N=146, Not yet recruiting, The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University
    New P2 trial
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    3d
    A Multicenter Phase I Clinical Study of CD19-Targeted CAR-NK Cell Therapy for Moderate to Severe Active Systemic Lupus Erythematosus in China. (ChiCTR2600116668)
    P1, N=36, Not yet recruiting, Peking Union Medical College Hospital; Ruitherapeutics Co., LTD
    New P1 trial
    |
    MET positive
    |
    KN5501
    4d
    Research Progress on the KMT2A-AFF3 Fusion Gene in Childhood Acute Lymphoblastic Leukemia: Mechanisms, Clinical Implications, and Therapeutic Strategies. (PubMed, Curr Issues Mol Biol)
    This review highlights the evidence defining its poor prognosis, which is primarily driven by profound chemoresistance to conventional therapies, including glucocorticoids. Finally, we discuss the rapidly evolving therapeutic landscape, detailing the limitations of standard intensive chemotherapy and the immense promise of novel targeted strategies, such as Menin inhibitors (e.g., Revumenib), DOT1L inhibitors, and immunotherapies (e.g., CAR-T cells, Blinatumomab), which hold the potential to revolutionize outcomes for this high-risk leukemia subtype.
    Review • Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1) • MEIS1 (Meis Homeobox 1) • MME (Membrane Metalloendopeptidase) • DOT1L (DOT1 Like Histone Lysine Methyltransferase) • AFF3 (AF4/FMR2 Family Member 3)
    |
    Blincyto (blinatumomab) • Revuforj (revumenib)
    4d
    topMIND: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=54, Terminated, Incyte Corporation | Completed --> Terminated; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
    Trial termination • Pan tumor
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Chr t(11;14)
    |
    parsaclisib (INCB50465) • Monjuvi (tafasitamab-cxix)
    5d
    ELEVATE-1: A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, GlaxoSmithKline
    New P1 trial
    |
    GSK5926371
    8d
    SOHO State of the Art Updates and Next Questions | SOHO 2025 Next Questions: Acute Lymphoblastic Leukemia. (PubMed, Clin Lymphoma Myeloma Leuk)
    Novel agents under development include the subcutaneous (SC) form of blinatumomab, which has demonstrated efficacy even in patients with prior blinatumomab exposure. Altogether, these developments frame the next set of questions in ALL, which will be addressed in this review.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Blincyto (blinatumomab)
    10d
    Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. (PubMed, Nephrol Dial Transplant)
    We furthermore discuss genetically engineered CD38 knock-out multitarget natural killer cells, expressing anti-B cell maturation antigen (BCMA) CAR, IL-15RF and hnCD16, administered in combination with daratumumab (anti-CD38) in this context...Likewise, we hypothesize the use of bi-specific T cell engagers such as CD19 blinatumomab or BCMA teclistamab for the treatment of AMR...In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.
    Journal
    |
    IL6 (Interleukin 6) • CD40LG (CD40 ligand)
    |
    Blincyto (blinatumomab) • Darzalex (daratumumab) • Tecvayli (teclistamab-cqyv)
    10d
    A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    11d
    KN5501 Cell Injection for Refractory SLE(CLEAR) (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Ruitherapeutics Co., LTD
    New P1 trial
    |
    KN5501
    11d
    Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia. (PubMed, Leukemia)
    Patients remaining on dasatinib maintained elevated NK cells with a more mature phenotype, suggesting a durable effect. These results highlight the greater dasa+blina immune activation, supporting a potential synergistic effect of the drug combination.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    dasatinib • Iclusig (ponatinib) • Blincyto (blinatumomab)
    12d
    Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) (clinicaltrials.gov)
    P2, N=78, Recruiting, West Virginia University | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    The timing of concurrent intrathecal chemotherapy during blinatumomab infusion influences neurotoxicity in pediatric acute lymphoblastic leukemia. (PubMed, Front Immunol)
    Multivariate analysis identified Day 1 concurrent IT administration as an independent risk factor (OR = 12.5; 95% CI: 1.45-131; p = 0.023). Initiating IT chemotherapy on the same day as blinatumomab infusion significantly increases the risk of neurotoxicity in pediatric ALL patients.
    Retrospective data • Journal
    |
    CD4 (CD4 Molecule)
    |
    Blincyto (blinatumomab)